Nature Communications · 2024 · 55 citations · 30 references
MedicineImmunologyOncologyAdaptive ImmunityCancer ImmunologyInnate ImmunityAdaptive Immune ResponsesCancer ImmunotherapyCancer VaccinesNanoparticle-based ImmunotechnologyTumor Microenvironment ModulationVaccine PlatformsAdaptive Antitumor ImmunityAdaptive Immune Responses To BacteriaAntitumor Immune ActivationBacterial Immune ResponsesGlioblastoma ImmunotherapyImmune Response InductionInnate Antitumor ImmunityPyroptosis Mechanisms
Glioblastoma multiforme (GBM) is a highly aggressive brain tumor characterized by invasive behavior and a compromised immune response, presenting treatment challenges. Surgical debulking of GBM fails to address its highly infiltrative nature, leaving neoplastic satellites in an environment characterized by impaired immune surveillance, ultimately paving the way for tumor recurrence. Tracking and eradicating residual GBM cells by boosting antitumor immunity is critical for preventing postoperative relapse, but effective immunotherapeutic strategies remain elusive. Here, we report a cavity-injectable bacterium-hydrogel superstructure that targets GBM satellites around the cavity, triggers GBM pyroptosis, and initiates innate and adaptive immune responses, which prevent postoperative GBM relapse in male mice. The immunostimulatory Salmonella delivery vehicles (SDVs) engineered from attenuated Salmonella typhimurium (VNP20009) seek and attack GBM cells. Salmonella lysis-inducing nanocapsules (SLINs), designed to trigger autolysis, are tethered to the SDVs, eliciting antitumor immune response through the intracellular release of bacterial components. Furthermore, SDVs and SLINs administration via intracavitary injection of the ATP-responsive hydrogel can recruit phagocytes and promote antigen presentation, initiating an adaptive immune response. Therefore, our work offers a local bacteriotherapy for stimulating anti-GBM immunity, with potential applicability for patients facing malignancies at a high risk of recurrence.
30
Optically-controlled bacterial metabolite for cancer therapy
Diwei Zheng, Ying Chen, Zi-Hao Li et al. · Nature Communications · 2018 · 327 citations · Full text
Giuseppe Minniti, Dante Amelio, Maurizio Amichetti et al. · Radiotherapy and Oncology · 2010 · 320 citations